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Abstract 
The association between altered gut microbiota, intestinal permeability, inflammation and 
cardiometabolic diseases is becoming increasingly clear but remains poorly understood1,2. 
Indoleamine 2, 3-dioxygenase (IDO) is an enzyme induced in many types of immune cells 
including macrophages in response to inflammatory stimuli, and catalyses the degradation of 
tryptophan (Trp) along the kynurenine (Kyn) pathway. IDO activity is better known for its 
suppression of effector T-cell immunity and its activation of regulatory T cells3,4. However, high 
IDO activity predicts worse cardiovascular outcome5-9 and may promote atherosclerosis and 
vascular inflammation6, suggesting a more complex role in chronic inflammatory settings. IDO 
activity is also increased in obesity10-13. Yet, the role of IDO in metabolic disease is still 
unexplored. Here we show that obesity is associated with an increase of intestinal IDO activity, 
which shifts Trp metabolism from indole derivative and interleukin (IL)-22 production towards 
Kyn production. IDO deletion or inhibition improves insulin sensitivity, preserves gut mucosal 
barrier, decreases endotoxaemia and chronic inflammation, and regulates lipid metabolism in 
liver and adipose tissues. These beneficial effects are due to rewiring of Trp metabolism towards 
a microbiota-dependent production of IL-22 and are abrogated after treatment with a 
neutralizing anti-IL-22 antibody. In summary, we identify an unexpected function of IDO in the 
fine tuning of intestinal Trp metabolism with major consequences on microbiota-dependent 
control of metabolic disease, which suggests IDO as a potential therapeutic target. 
 
To address the role of IDO in obesity, we used high fat diet (HFD) to promote metabolic disease in 
wild-type (WT) and Ido1-/- mice. HFD -fed WT mice compared to those on a normal chow diet (NCD) 
induced Ido1 mRNA in epididymal (epi) and inguinal (ing) white adipose tissue (WAT) as well as in 
soleus muscle (Supplementary Fig. 1a), whereas no Ido1 mRNA was detected in liver (data not 
shown). Of note, IFN-γ, known as a potent inducer of IDO14 was also higher in the HFD-fed mice 
compared to those on a NCD (Supplementary Fig. 1b). Accordingly, we found that HFD-feeding 
resulted in  significantly greater IDO activity (as assessed by measurement of Kyn/Trp ratio) in 
plasma, epiWAT, brown adipose tissue (AT) and the soleus muscle, in comparison to WT mice on a 
NCD (Fig. 1a).  
Ido1-/- mice fed a NCD showed no major differences in body mass, adiposity and insulin sensitivity 
compared to WT on the same diet (Supplementary Fig. 2). Interestingly, when put on a HFD, Ido1-/- 
mice still had a similar weight curve as WT or Ido1-/- mice fed a NCD (Fig. 1b) and had a lower fat 
mass as evaluated by magnetic resonance imaging (MRI), as compared to HFD-fed WT mice (Fig. 
1c), without any change in lean mass (Supplementary Fig. 3a). In particular, the weights of epiWAT, 
inguinal (ing) WAT and retroperitoneal (ret) WAT were lower in HFD-fed Ido1-/- mice compared to 
HFD-fed WT mice (Fig. 1d). Consistent with lower adiposity and plasma leptin levels 15 (Fig. 1e), 
HFD-fed Ido1-/- mice compared to WT on the same diet also had lower liver weights (Fig. 1f), and 
their livers were characterized by less lipid accumulation (Fig. 1g), and lower macrophage infiltration 
(Supplementary Fig. 3b), indicating a protection from liver steatosis.  
Obesity is known to contribute to the development of adipose tissue inflammation leading to insulin 
resistance16,17. Examination of ingWAT and epiWAT revealed less macrophage infiltration (Fig. 1h), 
and higher content of CD11b+F4/80+CD206+ M2-like macrophages in epiWAT (Fig. 1i), with no 
change of CD11b+F4/80+CD11c+ M1-like (data not shown), in HFD-fed Ido1-/- mice compared to 
WT on the same diet. Similarly, epiWAT explants from HFD-fed Ido1-/- mice produced higher levels 
of protective adiponectin18 (Fig. 1j) compared to explants from WT mice on the same diet, whereas 
ingWAT produced higher type 2 immune cytokines IL-10, IL-4 and IL-5 (ref. 17) (Supplementary 
Fig. 3c), indicating a lower inflammatory status in adipose tissues of HFD-fed Ido1-/- mice compared 
to HFD-fed WT. Consistent with lower fat mass, insulin concentrations were lesser in fasting HFD-fed 
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Ido1-/- mice compared to WT on the same diet and during oral glucose tolerance test (OGTT) 
(Supplementary Fig. 3d). HFD-fed Ido1-/- mice also showed improved insulin tolerance test (ITT) 
(Fig. 1k), lower AUC insulin/AUC glucose (Fig. 1l) and better insulin signalling (P-AKT) in the 
soleus muscle (Fig. 1m), but not in liver, ingWAT and epiWAT (Supplementary Fig. 3e), compared 
to HFD-fed WT mice. These results indicated that HFD-fed Ido1-/- mice were protected from obesity 
and related metabolic complications, including liver steatosis and insulin resistance. 
To explain the weight differences between HFD-fed Ido1-/- mice and their controls, we performed 
detailed metabolic analyses. Covariate analysis of relationship between body weight and energy 
expenditure revealed a significant difference between HFD-fed WT and HFD-fed Ido1-/- mice pointing 
towards a higher metabolic efficiency in absence of IDO without any change in food intake and total 
energy excretion (Supplementary Fig. 3f-h), and any difference in spontaneous locomotor activity or 
preferential substrate use (data not shown). To determine which tissues contributed to the higher 
energy expenditure, we used positron emission tomography-computed tomography (PET-CT). 18F 
fluorodeoxyglucose (FDG) uptake was higher in the muscle of HFD-fed Ido1-/- mice compared to 
HFD-fed WT, without any observed differences in brain, brown AT and heart (Fig. 1n). This is in 
agreement with higher membrane glucose transporter type 4 (GLUT4) expression, mitochondrial 
marker staining, and greater adenosine triphosphate (ATP) production in soleus muscle of HFD-fed 
Ido1-/- mice compared to HFD-fed WT mice (Supplementary Fig. 4), suggesting a higher muscular 
metabolic rate. 
Then, we sought to inhibit IDO activity using L-1Methyl Tryptophan (1MT) in drinking water. We 
found no differences in body weight in 1MT- treated WT mice compared to untreated mice fed with a 
HFD (Supplementary Fig. 5a) that may due to several factors such as the duration, extent and 
sustainability of IDO inhibition. However, HFD-fed WT mice treated with 1MT showed lower plasma 
IDO activity (as measured by the Kyn/Trp ratio), a higher production of adiponectin by epiWAT 
explants, improved insulin tolerance, and a lower insulin-resistance index (HOMA-IR), compared to 
untreated WT mice (Supplementary Fig. 5b-e). We observed similar results in genetically obese 
leptin-deficient (ob/ob) mice treated with 1MT compared to untreated ob/ob mice (Supplementary 
Fig. 5f-g), indicating that the inhibition of IDO activity improved insulin resistance in obesity. 
IDO is expressed by both myeloid and non-myeloid compartments 4,19. To distinguish between the 
roles of IDO in those compartments, we generated chimeric mice. Reconstitution of WT mice with 
bone marrow from Ido1-/- mice compared to bone marrow from WT mice only slightly affected plasma 
IDO activity (i.e., the Kyn/Trp ratio) (Fig. 2a), mouse body weight, WAT weights and insulin 
sensitivity (Fig. 2b-d). Moreover, mice deleted for IDO in macrophages (Ido1flox/flox LysM-cre), the 
main cells that express IDO in the myeloid compartment 14, showed similar weight curves and insulin 
sensitivity, compared to HFD-fed Ido1flox/flox  control mice, indicating that IDO in myeloid 
compartment is dispensable for obesity and insulin-resistance (Supplementary Fig. 6). Interestingly, 
mice deficient for IDO in non-myeloid cells had a marked lower plasma IDO activity (Kyn/Trp) (Fig. 
2a), gained less body weight on HFD and had lower ingWAT, epiWAT, retWAT and liver weights 
(Fig. 2b-c), as well as improved insulin tolerance and glucose homeostasis (Fig. 2d-e), compared to 
HFD-fed WT mice transplanted with WT bone marrow. The results strongly support the importance of 
IDO expressed in non-myeloid compartment in the induction of metabolic disease. 
Increased gut-derived lipopolysaccharide (LPS) translocation and intestinal dysbiosis were observed in 
obesity20. Since IDO is expressed in the gastrointestinal tract19, we analyzed intestinal IDO activity 
during HFD feeding. HFD feeding resulted  in a markedly greater IDO activity (as measured by 
changes in the Kyn/Trp ratio) in both the small intestine and colon (Fig. 2f). We therefore 
hypothesised that intestinal IDO activity may hijack local Trp metabolism and shift it away from use 
by the gut microbiota. 
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To address the importance of the microbiota, we depleted the gut microbiota in HFD- fed WT and 
Ido1-/- mice using a broad spectrum antibiotic cocktail supplemented in drinking water. In agreement 
with a previous study21, depletion of the microbiota protected the mice against HFD-induced weight 
gain (Fig. 2g). Moreover, antibiotic treatment abrogated the differences of body weight previously 
seen between HFD-fed WT and HFD-fed Ido1-/- mice (Fig. 2g). To test whether the gut microbiota is 
involved in the phenotype, WT and Ido1-/- mice were co-housed after weaning (mix) and compared to 
mice housed in cages separated by genotype. As shown in Fig. 2h, the weight of co-housed animals 
(whether WT or Ido1-/-) was similar to those of Ido1-/- mice housed in separate cages, indicating a 
dominant protective effect against weight gain of microbiota from Ido1-/- mice. Moreover, antibiotic 
treatment and co-housing abrogated the genotype-related differences in HOMA-IR (Fig. 2i). 
We then sought to explore whether microbiota transfer might suffice to recapitulate the phenotype 
observed in HFD-fed Ido1-/- mice. We thus forced-fed WT mice with feces collected from ob/ob mice 
treated or not with 1MT. We used ob/ob mice because they are already obese and they showed 
improved insulin sensitivity but no difference in body weight in response to 1MT treatment (data not 
shown), in association with a significant lower Kyn/Trp ratio in the feces (Fig. 2j). As shown in Fig. 
2k-n, repetitive gavage of WT mice with feces from 1MT-treated ob/ob mice led to a lower increase 
of total body, WAT and liver weights, to a higher content of M2-like macrophages in epiWAT, and a 
lower HOMA-IR, compared to WT mice transferred with feces from control ob/ob mice, indicating 
protective effects of microbiota collected from mice treated with IDO inhibitor. 
We next explored the bacterial fecal composition of the microbiota by use of 16S rDNA sequencing. 
Principal component analysis (PCA) on the basis of genus composition revealed major differences 
between WT and Ido1-/- mice fed with HFD (Fig. 3a) and between ob/ob mice treated or not with 1MT 
(Supplementary Fig. 7a). No differences regarding bacterial biodiversity were observed between WT 
and Ido1-/- mice fed with HFD, and between ob/ob mice treated or not with 1MT (Supplementary Fig. 
7b). At the phylum level, important differences were observed between WT and Ido1-/- mice fed with 
either a NCD or a HFD (Fig. 3b). In particular, we found that the HFD led to higher Firmicutes to 
Bacteroidetes ratio in WT mice, as previously reported22, whereas HFD-fed Ido1-/- mice showed a 
reduction of this ratio, compared to NCD-fed Ido1-/- mice (Fig. 3b). At the family level, significantly 
greater proportions of Ruminococcaeae and lower proportions of Rikenellaceae were observed in 
HFD-fed WT mice compared to NCD-fed WT mice (Fig. 3c), in agreement with previous reports23,24. 
Whereas in HFD-fed Ido1-/- mice compared to NCD-fed Ido1-/- mice, the decrease of Firmicutes was 
mainly due to a lower proportion of Clostridiales, in particular Lachnospiraceae (Fig. 3c and 
Supplementary Fig. 7c). The decrease of Lachnospiraceae was also observed on 1MT-treated ob/ob 
mice compared to untreated mice (Supplementary Fig. 7d). Moreover, a positive correlation was 
observed between the proportion of Clostridiales lachnospiraceae in feces and LPS levels in plasma 
(Supplementary Fig. 7e), suggesting a beneficial impact of the decrease of a selective bacterial 
species on inflammation in HFD-fed Ido1-/-and 1MT-treated ob/ob mice. These results were 
confirmed, using the linear discriminant analysis (LDA) effect size (LEFSE) pipeline comparing 
HFD-fed WT and HFD-fed Ido1-/- mice (Supplementary Fig. 7f). Overall, these data demonstrate that 
IDO has an important role in shaping gut microbiota, which is required to control body weight and 
insulin-resistance. 
We next examined whether Kyn or derived metabolites played a direct role in obesity, as previously 
suggested25. In particular, administration of kynurenic acid (Kna), a metabolite downstream of Kyn, to 
WT mice has been shown to activate G protein-coupled receptor (GPR) 35 and rises energy 
expenditure26. To this end, we supplemented Ido1-/- mice with Kyn or Kna added in drinking water. 
Kyn supplementation in Ido1-/-  mice did not change body weight, WAT weights or insulin sensitivity 
despite a higher plasma Kyn levels (Supplementary Fig. 8). Moreover, Kna supplementation in Ido1-
/- mice did not alter body weight (data not shown). Our results indicate that the absence of Kyn or 
derived metabolites in Ido1-/- mice does not explain the observed protection against metabolic disease.  
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Trp is either metabolized by IDO to produce Kyn or by gut bacteria into indole derivatives, such as 
indole-3-acetic acid (IAA) that activates aryl hydrocarbon receptor (AHR)27 (Supplementary Fig. 
9a). We hypothesised that in obesity the increase of IDO activity shifts Trp metabolism from 
generation of indole derivatives towards Kyn production. To test this, we examined intestinal content 
of IAA, Trp and Kyn in NCD or HFD-fed WT or Ido1-/- mice, ob/ob mice treated or not with 1MT, 
and in WT mice that received feces from 1MT-treated or untreated ob/ob mice. As shown in Fig. 3d, 
HFD in WT mice led to lower intestinal content of IAA, whereas it markedly induced Kyn levels in 
the gastrointestinal tract, indicating that HFD-induced obesity causes a major shift of Trp metabolism 
towards Kyn production. Consistently, in the case of a low level of intestinal Kyn as in HFD-fed Ido1-
/- mice (Fig. 3d) and in 1MT-treated ob/ob mice (Supplementary Fig. 9b), a substantially higher IAA 
intestinal content was observed, as compared with HFD-fed WT mice (Fig. 3d) and control ob/ob 
mice (Supplementary Fig.9c), without major changes of intestinal Trp levels (Supplementary Fig. 
9d-e). Moreover, a higher intestinal IAA was observed in WT mice that received feces from 1MT-
treated mice compared to non-treated mice (Supplementary Fig. 9f), indicating the importance of 
IDO-dependent changes of microbiota in IAA production. Using an AHR reporter system, we found 
that small intestines contents of HFD-fed Ido1-/- mice activated AHR more than those recovered from 
HFD-fed WT mice (Supplementary Fig. 9g). This data supports the importance of IDO in controlling 
Kyn and IAA-activating AHR balance. Moreover, AHR activation or IAA supplementation in WT 
mice fed a HFD reduced insulin resistance and epiWAT inflammation (Supplementary Fig. 10a-f), 
without significant changes in body weight (data not shown). 
We then explored the role of the 2 cytokines related to indole metabolites27, IL-17 and IL-22, in our 
findings. In agreement with previous reports showing that HFD diminished IL-17 and IL-22 (ref. 28, 
29), we found lower levels of these cytokines in Peyer’s patches (PP) of HFD-fed WT compared to 
NCD-fed WT mice (Fig. 3e). Moreover, in agreement with higher IAA27, we observed more IL-17 and 
IL-22 in HFD-fed Ido1-/- mice compared to HFD-fed WT (Fig. 3e) as well as more IL-22 in 1MT-
treated WT mice compared to non-treated mice (Supplementary Fig. 10g). Furthermore, a higher 
intestinal IL-22 level was observed in WT mice that received feces from 1MT-treated ob/ob mice 
compared to non-treated ob/ob mice (Supplementary Fig. 10h). Intestinal IAA levels were positively 
correlated with intestinal IL-22 levels and negatively with HOMA-IR (Supplementary Fig. 10i-j). 
We further found an increase of IL-22-target genes such as antimicrobial proteins30, regenerating islet-
derived (Reg)3g, Reg3b mRNA (Fig. 3f) in intestines of HFD-fed Ido1-/- compared to HFD-fed WT 
mice. Short-chain fatty acids (SCFAs), mainly acetate, propionate and butyrate, are the end products 
of fermentation of dietary fibres by the anaerobic intestinal microbiota, and have been shown to exert 
multiple beneficial effects2. Interestingly, a higher fecal level of SCFAs was observed in HFD-fed 
Ido1-/- compared to WT mice fed with the same diet (Fig. 3g) supporting a restoration of the intestinal 
ecosystem. Moreover, we observed lower expression of inflammation-associated genes (differentially 
expressed between HFD-fed WT and Ido1-/- mice) in intestines of HFD-fed Ido1-/- compared to HFD-
fed WT mice, using NanoString technology (Fig. 3h). As previously published20, we found that HFD 
led to a higher plasma LPS (Fig. 3i). However, HFD-fed Ido1-/- mice showed lower plasma LPS in 
comparison to HFD-fed WT mice (Fig. 3i), which was also the case in 1MT-treated WT and ob/ob 
mice compared to untreated controls (data not shown). Altogether these results provide a strong 
evidence for a protective role of IDO deletion in preserving intestinal immune barrier during obesity. 
IL-22 was shown to exert essential roles in eliciting antimicrobial immunity and maintaining mucosal 
barrier integrity within the intestine31,32. Given the observed higher levels of IL-22 in HFD-fed Ido1-/- 
mice compared to HFD-fed WT mice, we injected mouse anti-IL-22 neutralizing antibody or control 
IgG1 to WT and Ido1-/- mice during HFD period. Neutralization of IL-22 in HFD-fed Ido1-/- mice 
compared to HFD-fed WT mice abrogated the protective effects of IDO deletion on obesity, insulin 
sensitivity and intestinal permeability (Fig. 3j-o and Supplementary Fig. 11).  
As rodents may differ from humans regarding the regulation of IDO activity33, we then explored the 
relevance of our data in the human setting of obesity (Supplementary Table). In line with the 
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dysfunction of gut barrier function in obesity, we detected a higher circulating endotoxin level in 
subjects with obesity in comparison with non-obese individuals (Fig. 4a). Moreover, plasma Kyn level 
was higher in subjects with obesity or with type 2 diabetes compared to controls (Fig. 4b). We then 
analysed for the first time the levels of fecal Trp, Kyn and IAA in the context of human obesity. In 
agreement with our mouse data, we observed a shift of Trp metabolism towards more Kyn and less 
IAA in feces of subjects with obesity or diabetes compared to non-obese subjects (Fig. 4c). We found 
no correlation between plasma and feces levels of Kyn/Trp ratio (r = 0.04, P = 0.75), suggesting a 
specific micro-environmental regulation of IDO in intestine of subjects with obesity. We then 
examined correlations between feces or plasma Kyn levels and metabolic and clinical parameters in 
subjects with obesity. We found positive correlations between plasma Kyn and body weight (r = 0.37, 
P = 0.007), waist-circumference (r = 0.34, P = 0.01), fat mass (r = 0.38, P = 0.01), plasma LPS (r = 
0.31, P = 0.02), aspartate aminotransferase AST (r = 0.34, P = 0.02), area under the curve during an 
oral glucose tolerance test (r = 0.37,  P = 0.008), but negative correlations with HDL-cholesterol (r = -
0.31, P = 0.03) and glucose rate during euglycemic hyperinsulinemic clamp (r = -0.40, P = 0.006). We 
observed an inverse correlation between feces Kyn levels and HDL-cholesterol (r = -0.35, P = 0.01), 
but detected positive correlations between feces Kyn levels and plasma triglycerides (r = 0.38, P = 
0.007), and triglycerides/HDL-cholesterol ratio (r = 0.42,  P = 0.002), the latter being a surrogate 
marker for cardiometabolic risk34. These data indicate that high levels of Kyn in plasma and feces are 
associated with a deleterious metabolic profile in the setting of obesity. 
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Figure Legends  
Figure 1 Ido1-/- mice are protected from obesity, inflammation, liver steatosis and insulin resistance. 
(a) IDO activity (Kyn/Trp ratio) in plasma, ingWAT, epiWAT, brown AT, liver and soleus from WT 
mice fed with either a HFD (n = 5) or a NCD (n = 5) or HFD-fed Ido1-/- mice after 20 weeks. HFD-fed 
Ido1-/- mice values are displayed only as controls. (b) body mass of WT and Ido1-/- mice fed with either 
HFD (n = 10 per group) or NCD (n = 5 per group) during 20 weeks.. This result was confirmed in a 
total of 4 independent experiments. (c-f) Body fat % (c), weights in grams of epiWAT, ingWAT and 
retWAT (d), plasma leptin (e) and liver weight (f) of WT and Ido1-/- mice fed with HFD during 20 
weeks. (g) Representative pictures (left) and quantification (right) of lipid areas in liver cross-sections 
from HFD-fed WT and Ido1-/- mice (n = 9 per group). Scale bars, 100 µm. (h) Representative images 
(left) and quantifications (right) of F4/80 staining in ingWAT and epiWAT (n = 5 per group). Scale 
bars, 100 µm. F4/80 staining (in red) was normalized on Plin1 staining (in green). (i-l) quantification 
of M2-like macrophages (F4/80+CD11b+CD206+) in epiWAT (n = 5 per group) (i), adiponectin 
production by epiWAT explants (n = 10 per group) (j), insulin tolerance test (ITT) adjusted on body 
weight (confirmed in a total of 3 independent experiments) (k), ratio of area under curve (AUC) of 
insulin to AUC glucose during oral glucose tolerance test (OGTT) in WT and Ido1-/- mice fed with 
HFD during 20 weeks (n = 10 per group) (l). (m) Insulin signaling (pAKT-S473) in soleus after 15 
min of 5 U/kg insulin injection. Cropped blot images are shown, the full scans are available in 
Supplementary Fig. 12. The result is representative of two independent experiments. (n) 
Representative FDG-PET images (left) and quantification (right) of tissue FDG uptake in WT and 
Ido1-/- mice fed with HFD during 14 weeks (n = 5 per group). SUV, standardized uptake values. White 
arrows show the FDG uptake in muscle. Data are expressed as mean ± sem. Mann-Whitney test (a-l) 
or two-tailed unpaired Student's t-test	  (n) was used for statistical analysis. *P < 0.05, **P < 0.001, 
***P < 0.0001.  
Figure 2 IDO activity controls gut microbiota-dependent regulation of obesity and its complications. 
(a-e) IDO activity (Kyn/Trp ratio) in plasma (n = 5 per group) (a), % of weight gain (b), weights in 
grams of ingWAT, epiWAT, retWAT and liver (c), insulin test tolerance (ITT) (d), oral glucose 
tolerance test (OGTT) (e) in WT mice irradiated and transplanted with either WT or Ido1-/- bone 
marrow (Ido1-/--> WT (n = 10) and WT -> WT (n = 10) groups) or Ido1-/- mice irradiated and 
transplanted with WT bone marrow (WT -> Ido1-/- (n = 10)) after 20 weeks of HFD. (f) IDO activity 
(i.e. Kyn/Trp) in small intestines and colons of WT mice fed with either a NCD (n = 5) or a HFD (n = 
4) and HFD-fed Ido1-/- mice (n = 4). (g-i) weight curves (non-mixed and non-treated HFD-fed WT and 
Ido1-/- mice weight curves are displayed only as controls), (g and h) HOMA-IR index normalized to 
body weight of WT and Ido1-/- mice either on antibiotic treatment (Ab) (n = 10 per group) or WT and 
Ido1-/- mice mixed in the same cages from 4 weeks of age (mix) (n = 8 per group) or WT and Ido1-/- 
mice untreated and separated in different cages (n = 10 per group) (i). (j-n) gavage of WT mice with 
feces from 1MT-treated or not treated ob/ob mice (n = 10 per group). Ratio of Kyn/Trp in feces of 
1MT-treated or not treated ob/ob mice (n = 4 per group) (j), body mass (k), weights in grams of 
ingWAT, epiWAT, retWAT and liver (l), representative cytometry (left) and quantification (right) of 
M2-like macrophages (F4/80+CD11b+CD206+) in epiWAT (n = 5 per group) (m) and HOMA-IR in 
WT mice that received feces from 1MT-treated or untreated ob/ob mice (n = 10 per group). n.s., non-
significant. Data are expressed as mean ± sem. Mann-Whitney test was used for statistical analysis (a-
n). *P < 0.05, **P < 0.001, ***P < 0.0001. 
Figure 3 IDO deficiency preserves the intestinal barrier through IL-22 in the setting of obesity. (a) 
PCA plot based on bacterial 16S rDNA gene sequence abundance in fecal content of WT and Ido1-/- 
mice fed with either a NCD or a HFD. Axes correspond to principal components 1 (x-axis), 2 (y-axis) 
and 3 (z-axis). (b, c) bacterial-taxon-based analysis at the phylum level (b) and at family level (c) in 
the fecal microbiota. (d) IAA (left) and Kyn (right) levels in small intestines and colons of WT fed 
with either a NCD (n = 5) or a HFD (n = 4) and HFD-fed Ido1-/- mice (n = 4). (e) IL-17 (left) and IL-
11	  
	  
22 (right) contents in Peyer’s patches (PP) of WT and Ido1-/- mice fed with either a NCD (n = 4 per 
group) or a HFD (n = 3 per group). The result was confirmed in two independent experiments. (f) 
Reg3b (left) and 3g (right) mRNA in intestines of HFD-fed WT (n = 3) and Ido1-/- mice (n = 4). (g) 
SCFA contents in the fecal microbiota from HFD-fed WT (n = 10) and Ido1-/- mice (n = 9). The result 
is a pool of 2 independent experiments. (h) The heat map generated using the hierarchical clustering 
shows expression of genes differentially expressed in intestines of HFD-fed WT (n = 3) and Ido1-/- 
mice (n = 4). (i) Plasma LPS in WT and Ido1-/- mice fed with either NCD or HFD (n = 5 per group) 
after 20 weeks. The result was confirmed in two independent experiments. (j-n) % of weight gain after 
12 weeks of HFD (j), OGTT (k), ITT (l), HOMA-IR (m), liver steatosis (n) and plasma LPS (o) in 
WT and Ido1-/- mice injected with mouse anti-IL-22 neutralising antibody, 3 times per week during 12 
weeks of HFD. Scale Bars 100µM. Data are expressed as mean ± sem. Mann-Whitney test (d, g, i and 
m) or two-tailed unpaired Student's t-test	  (e and f) was used for statistical analysis. *P < 0.05, **P < 
0.001, ***P < 0.0001. 
Figure 4 A shift of Trp metabolism towards more Kyn and less IAA in the context of human obesity 
and type 2 diabetes. (a) plasma LPS, (b) plasma Trp (left) and Kyn (right) in subjects with obesity (n = 
49) or type 2 diabetes (n = 43) and non-obese individuals (n = 20). (c) Trp (left), Kyn (middle) and 
Kyn/Trp (right) in feces from subjects with obesity (n = 49) or type 2 diabetes (n = 43) and non-obese 
subjects (n = 34). (d) IAA contents in feces from subjects with obesity (n = 49) or type 2 diabetes (n = 
43) and non-obese subjects (n = 34). Mann-Whitney test (a) or Kruskal-Wallis (b-d) was used for 
statistical analysis. Data are expressed as mean ± sem. *P < 0.05, ***P < 0.0001. 
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Online  Methods 
Mice 
Male C57Bl/6 Ido1-/- mice were bought from the Jackson Laboratory (Jax) and bred in our facility. At 
weaning, mice were separated according to the genotype. Male ob/ob mice were bought from Janvier 
Laboratory at 4 weeks of age. To generate Ido1flox/flox LysM-Cre, Ido1flox/flox  mice were crossed to 
LysM-Cre mice. Mice were fed with either a normal chow diet (NCD) (A03, SAFE, France) or 
subjected to diet-induced obesity containing 60% FAT (E15742-347, SSNIFF, Germany). High fat 
diet (HFD) was started at 7 weeks of age and continued for 20 weeks or less with ad libitum access to 
water and food. For chimerism experiment, we subjected 10 weeks old C57Bl/6 WT and C57Bl/6 
Ido1-/- mice to medullar aplasia by 9.5 gray lethal total body irradiation. We repopulated the mice with 
an intravenous injection of bone marrow cells isolated from femurs and tibias of male C57Bl/6 WT 
and C57Bl/6 Ido1-/- mice. After 4 weeks of recovery, mice were fed a HFD for 20 weeks. In some 
experiments, IDO inhibitor (L-1methyl tryptophan, 1MT) (Sigma Aldrich) or IAA (indole acetic acid; 
Sigma Aldrich) was used at 2mg/ml diluted in drinking water. The 6-formylindolo(3,2-b)carbazole 
(Ficz; Sigma Aldrich) was resuspended in dimethyl sulfoxide (DMSO; Sigma Aldrich) and 
administered intraperitoneally (1 ug/mouse, 1-3 times per week) during 15 weeks of HFD. In another 
experiment, kynurenine (2 mg/ml diluted in drinking water) supplementation to Ido1-/- mice was 
performed during 15 weeks of HFD. We also subjected some mice to antibiotic treatment as described 
before35. All mice used in these experiments were bred and housed in a specific pathogen-free barrier 
facility. Animal experiments were performed according to the European directive (2010/63/UE) and to 
the institutional guidelines approved by the local ethics committee of the French authorities, the 
'Comité d'Ethique en Experimentation Animale' (CEEA) under the following number 17-018. 
In vivo Studies 
For oral glucose tolerance test (OGTT), mice were fasted overnight prior to an oral administration of 
1-5 g/kg glucose. Blood was sampled from the tail vein at 0, 5, 15, 30, 60, 90 and 120 min in order to 
assay glucose concentration (OneTouch Ultra glucometer, LifeScan Europe). At 0, 15, 30, 60 min tail 
vein blood was collected, plasma samples were stored at -20°C until they were analyzed for insulin 
concentration (Crystal Chem Inc., Downers Grove, USA). Insulin tolerance test (ITT) was performed 
in mice food deprived for 5 h prior to an intraperitonial injection of 1 U/kg insulin. Blood was sampled 
from the tail vein at 0, 5, 15, 30, 60 and 90 min in order to assay glucose concentration. For insulin 
signaling assays C57Bl/6 WT and C57Bl/6 Ido1-/- mice were fasted overnight and then treated by 
intraperitoneal injection with 5 U/kg insulin (15 min). Tissue samples were examined by immunoblot 
analysis by probing with antibodies to phospho-AKT, AKT (Cell Signaling). Experiments with fecal 
gavage were done with fresh stool samples from either ob/ob control mice or ob/ob mice 
supplemented with 1MT during 6 weeks until 19 weeks. Briefly, stool were suspended in water and 
sieved through a 70 µm cell strainer (BD). These fecal suspensions were inoculated to C57Bl/6 WT 
mice via oral gavage with 400 µL of fecal suspension 4-5 times per week during 15 weeks of HFD. 
For anti-IL-22 neutralizing antibody treatment, WT and Ido1-/- mice were injected intraperitoneally 
three times per week with mouse anti-IL22 neutralizing antibody (50 µg/mouse) (Genentech, South 
San Francisco, CA, USA) or an equivalent amount of isotype control (IgG1) (Genentech) for a period 
of 12 weeks of HFD.  
Analysis of metabolic parameters 
Blood glucose level was measured using a glucometer (OneTouch Ultra, LifeScan Europe). Plasma 
insulin (Crystal Chem Inc., Downers Grove, USA) and plasma leptin was determined by ELISA 
(R&D Systems). HOMA-IR in mice was calculated using the equation ((fasting glucose concentration 
x fasting insulin concentration)/405) as previously described36. Areas under the curve (AUCs) for 
glucose and insulin were calculated for both C57Bl/6 and C57Bl/6 Ido1-/- mice during the 2h OGTT 
using the trapezoid method37. LPS in plasma was measured with a colorimetric diagnostic kit (Pierce, 
USA).  
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Measurement of short chain fatty acids (SCFA) was performed as described previously38 with slight 
modifications. A stock solution of SCFA metabolites (Sigma Aldrich, France) was prepared and 
serially diluted to get 10 calibration solutions. A working solution of internal standards was prepared 
in 0.15 M NaOH to get the following final concentrations: 75 mmol/L of D3-acetate, 3.8 mmol/L of 
D5-propionate, 2.5 mmol/L of 13C-butyrate, 0.5 mmol/L of D9-valerate (Sigma Aldrich). Stool samples 
were weighed (~50 mg), dissolved in 200 µL of sodium hydroxide solution at 0.15 M (NaOH, Sigma 
Aldrich). Twenty microliters of the internal standard solution were added to stool samples and 
calibration solutions. Each sample was then acidified with 5 µL of hydroxide chloride 37% (Sigma 
Aldrich, France) and then extracted with 1.7 mL of diethyl ether (Biosolve, France). Samples were 
stirred gently for 1 hour and then centrifuged 2 min (5000 rpm, 4°C). The organic layers were 
transferred into 1.5 ml glass vials and SCFAs were derivatized with 20 µL of tert-butyldimethylsilyl 
imidazole (Sigma Aldrich, France). Samples were incubated 30 min at 60°C before analysis. Samples 
were finally analyzed by GC-MS (model 7890A-5975C, Agilent Technologies, France) using a 30 m × 
0.25 mm × 0.25 µm capillary column (HP1-MS, Agilent Technologies, France). The temperature 
program started at 50 °C for 1 min, ramped to 90°C at 5°C/min, then up to 300 °C at 70°C/min. 
Selected ion monitoring (SIM) mode was used to measure SCFA concentrations with ions at m/z 117 
(acetate), 120 (D3-acetate), 131 (propionate), 136 (D5-propionate), 145 (butyrate and isobutyrate), 146 
(13C-butyrate), 159 (valerate), 168 (D9- valerate). 
Immunohistochemical analyses 
Liver sections (7 µm) were used for Oil Red O coloration to visualize lipid accumulation and to 
perform CD68 staining. Briefly, sections were fixed 5 min in PFA prior to staining. Macrophages were 
detected using anti-CD68 antibody (AbD Serotec MCA1975) overnight at 4°C. Anti-Rat peroxydase 
polymer (Histofine) and IHC chromogen substrate (Thermo scientific) were used for revelation. 
Immediately after collection, adipose tissue samples were drop-fixed in formaldehyde solution for 24 
hours, then put through an automated carousel processor for dehydration, clearing and paraffin 
embedding (Leica). Briefly, tissue sections were dewaxed through three consecutive incubations (5 
min) in xylene and then dehydrated by three consecutive incubations (3 min) in 96–100% ethanol, 
followed by 2 washes (2 min) in de-ionized water. Sections were then incubated for 15 min at room 
temperature in 3% (v/v) hydrogen peroxide, followed by two washes (2 min) in de-ionized water. 
Photo-bleaching with 5 min under UV lamp and Oil Red O emersion for 2 min were applied to quench 
auto-fluorescence. Sections were then blocked for 30 min with Tris-buffered saline (TBS) solution and 
3% bovine serum albumin (w/v). Primary antibodies anti-F4/80 (1:50, Cl:A3-1, MCA497, AbD 
Serotec), anti-Plin1 (1:100, D1D8, 08/2016 Cell Signalling Technologies) diluted in TBS + 1% (w/v) 
BSA were applied for 2 h at room temperature, slides were then washed in TBS + 0.1% (v/v) Tween20 
three times for 5 min, and the secondary antibodies anti-Rat TRITC-conjugated secondary antibody 
(A18870, ThermoFisher); anti-Rabbit FITC-conjugated secondary antibody (F2765, Life 
Technologies) were applied for 1 h at room temperature in the dark. Slides were then washed in TBS + 
0.1% (v/v) Tween20 three times for 5 min, slides were mounted with VectaShield hardset mounting 
media with DAPI, slides were cured overnight at 4°C before imaging. Images were acquired on an 
Axiovert 200M microscope using appropriate filters. Quantitative expression of immunostainings was 
performed using positive pixels algorithm (Indica Labs) on digital slides (Zeiss). F4/80 staining is 
expressed as a ratio of Plin1 staining. Quantification method of random fields is an automated 
observer-independent process based on publicly accessible algorithms. Each biological replicate 
represented one slide, which was mounted with at least 3 tissue sections, representing 3 technical 
replicates, the mean of which was presented as the result per biological replicate. 
Frozen soleus muscle sections were stained according to standard immunofluorescence protocols. 
Briefly, transversal sections were brought to room temperature and fixed with 10% formalin for 10 
minutes, followed by permeabilisation through two 5 minute washes with Tris buffered saline (TBS) 
solution containing 0.5 % (v/v) Tween 20. Sections were then blocked with TBS solution containing 3 
% bovine serum albumin. Slides were incubated at 4°C in a humidified chamber overnight with anti-
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AIF at a 1:50 dilution in TBS containing 1% BSA (Sigma SAB3501107) or anti-GLUT4 (Cell 
Signaling 11/2008) antibodies. Following incubation slides were washed three times for 10 minutes 
with TBS and incubated in a humidified chamber for 2 hours at room temperature with the following 
secondary antibodies: AlexaFlour 647 goat-anti-rabbit at 1:200 in TBS containing 1% BSA (Life 
technologies A21244) and rabbit-anti-mouse at 1:200 in TBS containing 1% BSA (abcam ab150127). 
Slides were washed three times for 5 minutes with TBS. Slides were then mounted with Vectashield 
Hard-set mounting media containing DAPI. Whole slide scanning was carried out on a Zeiss Axioscan 
scanner and Zen software. Image quantification was carried out using Visiopharm software applied to 
whole tissue scans in an observer independent manner following definition of membrane and cytosolic 
regions. Unless otherwise stated, standard reagents were sourced from Sigma. Quantification was 
carried out through positive pixel counts of morphologically defined membrane and cytoplasmic 
regions with the use of Visiopharm software. 
Adipose cell isolation and flow cytometry analyses 
The stromal vascular fraction (SVF) containing mononuclear cells and preadipocytes was extracted 
from adipose tissue. Adipose tissue from mice was digested using 10 mL digestion solution (7 mL 
Hank’s Solution, 3 mL 7.5% BSA and 20 mg collagenase type II, Sigma). The digestion was 
performed at 37°C using a shaker at 100 rpm for 20 min. After digestion, the adipocyte fraction 
(floating) was isolated and the solution containing the SVF was centrifuged at 1500 rpm at 4°C for 5 
min. The SVF pellet was resuspended in 1 mL fluorescence-activated cell sorter (FACS) buffer. After 
15 min incubation with Fc Block (2.4G2, BD Biosciences), SVF cells were stained with appropriate 
antibodies conjugated to fluorochromes or isotype controls for 30 min at 4°C in the dark: CD45 (30-
F11), F4/80 (BM8), CD11b (M1/70), CMHII (M5/114.15.2) from eBiosciences, CD11c (HL3) from 
BD Biosciences and CD206 (C068C2) from Biolegend. Samples were acquired using an Fortessa 
cytometer (Becton Dickinson) and analyzed with FlowJo (TreeStar) software programs. 
Adipose tissue culture 
Mouse adipose tissue biopsies (0.1g) were minced and incubated in 1mL of endothelial cell basal 
medium (PromoCell) containing 1% bovine serum albumin, penicillin (100 U/mL) and streptomycin 
(100 U/mL). Adipose tissue-conditioned medium (ATCM) were recovered after 24h and stored at -
80°C until analysis. 
Cytokine quantification 
Cytokine concentrations from ATCM were analyzed using ELISA kits. Adiponectin, IL-17, IL-5 
ELISA kits were from R&D Sytems. IFN-γ, IL-6, IL-4 and IL-10 ELISA kits were bought from BD. 
IL-22 ELISA kit was from eBiosciences. IL-17 and IL-22 were measured in PPs (Peyer’s patches) or 
intestine extracts. Briefly, PPs or intestines were lysed in detergent buffer (RIPA) containing protease 
inhibitor (Roche). After centrifugation 13000 g – 10 min at 4°C, protein quantification was performed 
on supernatants and then supernatants were stored at -20° until ELISA assay. IFNγ levels in plasma 
and WAT were determined using the murine IFN-γ ELISA kit from Diaclone SAS (Besançon, France) 
and according to the manufacturer's instructions. 
Quantitative Real time PCR 
Macrophages and intestines were lysed in detergent buffer RLT and then subjected to RNA extraction 
and reverse transcription (Qiagen). Then, quantitative real-time PCR was performed on an ABI 
PRISM 7700 (Applied Biosystems) in triplicates. Cycle threshold for Gapdh (primers: Gapdh-R, 5’-
CGTCCCGTAGACAAAATGGTGAA-3’; Gapdh-L, 5’-GCCGTGAGTGGAGTCATACTGGAACA-
3’) was used to normalize gene expression. Primers for Ido1 are: Ido1-R, 5’-
ATATATGCGGAGAACGTGGAAAAAC-3’, Ido1-L, 5’-CAATCAAAGCAATCCCCACTGTATC-
3’. Reg3g-R 5′-TTCCTGTCCTCCATGATCAAAA-3′ and Reg3g-L 5′-
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CATCCACCTCTGTTGGGTTCA-3′; and Reg3b-R 5′-ATGCTGCTCTCCTGCCTGATG-3′ and 
Reg3b-L 5′-CTAATGCGTGCGGAGGGTATATTC-3. PCR conditions were 10 min at 95°C ; 35 
cycles of 95°C for 15 s, 60°C for 20 s and 72°C for 20 s and a final extension at 72°C for 20 s.  
Western blot analysis 
Tissue samples were lysed in detergent buffer (RIPA, Thermo Scientific) containing protease and 
phosphatase inhibitor mixture (Roche) and sodium orthovanadate. Proteins were separated on 4-12% 
NuPage Tris-Bis gels using NuPage MES-SDS running buffer (Invitrogen) and then were transferred 
onto nitrocellulose membranes. The filters were probed with antibodies directed against phospho-AKT 
(Cell Signaling #4060P), AKT (Cell Signaling #9272S). 
Indirect calorimetric measurements 
Calorimetry exploration was performed at the “Functional and Physiological Exploration” facility 
(Université Paris-Diderot) as previously described39. Briefly, body composition was assessed using an 
Echo Medical systems EchoMRI 100 (Whole Body Composition Analyser, EchoMRI, Houston, 
USA). Energy expenditure, oxygen consumption and carbon dioxide production, respiratory exchange 
ratio, food intake and homecage activity were obtained using calorimetric chambers (Labmaster, TSE 
Systems GmbH, Bad Homburg, Germany). Activity was recorded using infrared light beam-based 
locomotion monitoring system. Mice were individually housed, fed with a HFD (SSNIFF, Germany) 
and acclimated to the chambers and drinking and food holders for 48 hr before experimental 
measurements. Calorimetric data represent mean of at least 96 hr measurement.  
Extensive analysis of energy expenditure (kcal/hr) and VO2 consumption (mL/hr) was performed 
using a regression based approach, analysis of covariance (ANCOVA, Minitab 16, Paris France), as 
previously described40, to take account of the mass effects with body weight, lean mass and fat free 
mass as covariance. Whole body mass and lean body mass were found to be dependent variables (P > 
0.05 from Analysis of covariance). Total energy excretion in feces was estimated by bomb calorimetry 
(Phenomin facility). 
 
Intestinal content DNA extraction  
Fecal genomic DNA was extracted from the weighted stool samples using a method that was 
previously described27, which is based on the European MetaHIT DNA extraction method.  
 
16s rRNA gene sequencing 
16s rDNA gene sequencing of fecal DNA samples was performed as previously described27. Briefly, 
the V3-V4 region (16S (sense) 5′-TACGGRAGGCAGCAG-3′ and (antisense) 5′-
CTACCNGGGTATCTAAT-3′) was amplified and sequencing was done using an Illumina MiSeq 
platform (GenoScreen, Lille, France). Raw paired-end reads were subjected to the following process: 
(1) quality-filtering using the PRINSEQ-lite PERL script38 by truncating the bases from the 3′ end 
that did not exhibit a quality < 30 based on the Phred algorithm; (2) paired-end read assembly using 
FLASH (fast length adjustment of short reads to improve genome assemblies)41 with a minimum 
overlap of 30 bases and a 97% overlap identity; and (3) searching and removing both forward and 
reverse primer sequences using CutAdapt, with no mismatches allowed in the primers sequences. 
Assembled sequences for which perfect forward and reverse primers were not found were eliminated. 
Sequencing data were analyzed using the quantitative insights into microbial ecology (QIIME 1.9.1) 
software package. The sequences were assigned to OTUs using the UCLUST algorithm42 with a 97% 
threshold of pairwise identity and classified taxonomically using the Greengenes reference database43. 
Rarefraction was performed (8,000 sequences per sample) and used to compare abundance of OTUs 
across samples. Biodiversity indexes were used to assess alpha diversity and α and β diversities were 
estimated using phylogenetic diversity and unweighted UniFrac. Principal component analyses (PCA) 
of The Bray Curtis distance with each sample colored according to phenotype were built and used to 
assess the variation between experimental groups. The LDA effect size algorithm was used to identify 
taxa that are specific to experimental group44.  
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Luciferase assay 
The H1L1.1c2 cell line containing a stably integrated dioxin response elements (DRE)-driven firefly 
luciferase reporter plasmid pGudLuc1.1 has been described previously27. The cells were seeded in 96-
well plates at 7.5 × 104 cells/well in 100 µl of complete Dulbecco’s modified Eagle’s medium 
(DMEM) (with 10% heat-inactivated FCS, 50 IU/ml penicillin, and 50 µg/ml streptomycin; Sigma-
Aldrich) and cultured (37 °C, 10% CO2) for 24 h before treatment. This cell line tested negative for 
mycoplasma contamination and was used in this study to determine AHR activity of small intestine 
content. To assess agonistic activity, the cells were treated with small intestine content suspensions 
diluted at 1:10 in complete DMEM. Controls consisted of cells treated with DMEM as the negative 
control, or FICZ (Sigma) diluted in DMEM as the positive control. After 24 h of incubation, wells 
were washed with 100 µl PBS, and 50 µl Promega lysis buffer was added to each well. The plates 
were shaken for 30 min to lyse the cells. After adding 100 µl of luciferase reagent (Promega), 
luciferase activity was measured using a luminometer. The results were normalized based on the 
negative luciferase activity of the control. 
HPLC quantifications 
Thawed stools from mice were extracted as previously described45. L-tryptophan (Trp) and L-
kynurenine (Kyn) were measured via HPLC using a coulometric electrode array (ESA Coultronics, 
ESA Laboratories, Chelsford,MA, USA)46. Quantifications were performed by referencing calibration 
curves obtained with internal standards. Other compounds (IAA) were quantified via liquid 
chromatography coupled to mass spectrometry (LC-MS) by using a Waters ACQUITY 
ultraperformance liquid chromatography (UPLC) system equipped with a binary solvent delivery 
manager and sample manager (Waters Corporation, Milford, MA, USA) and that was coupled to a 
tandem quadrupole-time-of-flight (Q-TOF) mass spectrometer equipped with an electrospray interface 
(Waters Corporation). Compounds were identified by comparing with the accurate mass and the 
retention time of reference standards in our in-house library, and the accurate masses of the 
compounds were obtained from web-based resources, such as the Human Metabolome Database 
(http://www.hmdb.ca) and the METLIN database (http://metlin.scripps.edu). 
ATP measurements  
The firefly luciferase bioluminometric assay was used to measure the muscular ATP content as 
previously described47.  
2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) PET-CT Imaging 
Mice were anesthetized with isoflurane (IsoVet 100%; Centravet, France) in 100% O2 (4% isoflurane 
for induction; 1-2% for maintenance). Mice were weighted, and placed on a heated plate (Minerve, 
France). A customized catheter with a 26 G needle (Fischer Scientific, France) connected to a 5-cm 
polyethylene tubing (Tygon Microbore Tubing, 0.010" x 0.030"OD; Fisher Scientific, France) was 
installed in the lateral tail vein of the mice. 10 MBq of 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG; 
Gluscan, Advanced Applied Applications, France) in 200 µl of saline solution were injected in the 
mice. The mice were then put back in their cages and left awake for 30 min. Mice were anesthetized 
again and installed in the imaging bed of the PET/CT scan (nanoScan, Mediso, Hungary). CT scans 
were performed first using the following parameters: mode semi-circular, tension of 39kV, 720 
projections full scan, 300 ms per projection, binning 1:4. List-mode PET data were collected between 
45 and 60 min post injection of [18F]FDG, binned using a 5-ns time window, a 400- to 600-keV energy 
window, and a 1:5 coincidence mode. In vivo PET acquisitions were reconstructed using the Tera-
Tomo reconstruction engine (3D-OSEM based manufactured customized algorithm) with expectation 
maximization iterations, scatter and attenuation corrections. Images were analyzed using the software 
PMOD (PMOD Technologies LLC). Standardized Volume of Interest (VOI) was drawn in each organ 
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of interest and Standardized Uptake Values (SUV) were calculated by dividing the mean tissue 
radioactivity concentration by the injected dose and body weight.  
NanoString. 
NanoString analysis was performed and analyzed according to the manufacturer’s recommendations. 
Human population 
Feces from healthy non obese individuals were recruited in the Gastroenterology Department of the 
Saint Antoine Hospital (Paris, France) and provided informed consent. Plasmas were from healthy non 
obese individuals (n = 20) from EFS, HEGP hospital (Paris, France). 
49 women with morbid obesity were followed at the Endocrinology Service of the Hospital 
Universitari de Girona Dr Josep Trueta (Girona, Spain, n = 25) and at the Center for Atherosclerosis of 
Policlinico Tor Vergata University of Rome (Rome, Italy, n = 24). Pre-established inclusion criteria: 
all subjects were of Caucasian origin; the subjects reported a stable body weight 3 months preceding 
the study, were free of any infections 1 month before and had no systemic disease. Pre-established 
exclusion criteria: subjects with liver disease, specifically HCV infection and tumor disease, and 
subjects with thyroid dysfunction were excluded by biochemical workup. All subjects gave written 
informed consent, validated and approved by the ethical committee of the Hospital Universitari Dr 
Josep Trueta (Comitè d'Ètica d'Investigació Clínica) and Policlinico Tor 388 Vergata University of 
Rome (Comitato Etico Indipendente). 
 
Subjects with type 2 diabetes 
 
We recruited subjects with treatment-naive type 2 diabetes (T2D), as recently reported48. Inclusion 
criteria were: (i) aged between 18 and 65 years; (ii) T2D diagnosis in the previous 6 months, as 
defined by the American Diabetes Association Criteria; (iii) absence of systemic and metabolic 
disease other than T2D, and absence of infection within the previous month; (iv) absence of diet or 
medication that might interfere with glucose homeostasis, such as glucocorticoids or antibiotics in the 
previous 3 months; and (v) HbA1c lower than 9%. Exclusion criteria were: (i) clinically significant 
major systemic disease, including malignancy; (ii) clinical evidence of hemoglobinopathies or anemia; 
(iii) history of drug or alcohol abuse, defined as > 80 g/d in men and > 40 g/d in women; (iv) acute 
major cardiovascular event in the previous 6 months; (v) acute illnesses or current evidence of acute or 
chronic inflammatory or infective disease; and (vi) mental illness rendering the participants unable to 
understand the nature, scope, and possible consequences of the study. 
All individuals gave written informed consent. The experimental protocol was approved by the Ethics 
Committee and the Committee for Clinical Investigation of the Hospital Universitari Dr. Josep Trueta 
(Girona, Spain). We certify that all applicable institutional regulations concerning the ethical use of 
information and samples from human volunteers were followed during this research. Complete clinical 
trial registration is deposited in the EU clinical trials register (EudraCT number 2010-022394-34). We 
report here the findings in the baseline samples from these subjects before entering the trial. 
 
Analytical determinations (human) 
  
Total plasma cholesterol was measured by an enzymatic, colorimetric method through the cholesterol 
esterase/cholesterol oxidase/peroxidase reaction (Cobas CHOL2). HDL cholesterol was quantified by 
a homogeneous enzymatic colorimetric assay through the cholesterol esterase/cholesterol 
oxidase/peroxidase reaction (Cobas HDLC3). Total plasma triglycerides were measured by an 
enzymatic, colorimetric method with glycerol phosphate oxidase and peroxidase (Cobas TRIGL). 
Serum aspartate transaminase (AST) was measured by colorimetry using automated tests (Roche 
Diagnostics GmbH, Mannheim, Germany). Intra- and inter-assay coefficients of variation were < 4%. 
 
Euglycemic hyperinsulinemic clamp (human) 
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Insulin action was determined by the euglycemic hyperinsulinemic clamp. After an overnight fast, two 
catheters were inserted into an antecubital vein, one for each arm, used to administer constant 
infusions of glucose and insulin, and to obtain arterialized venous blood samples. A 2-h euglycemic 
hyperinsulinemic clamp was initiated by a two step primed infusion of insulin (80 mU/m2/min for 5 
min, 60 mU/m2/min for 5 min) immediately followed by a continuous infusion of insulin at a rate of 
40 mU/m2/min (regular insulin; Actrapid, Novo Nordisk, NJ). Glucose infusion began at minute 4 at 
an initial perfusion rate of 2 mg/kg/min, then was adjusted to maintain plasma glucose concentration at 
4.9–5.5 mmol/L. Blood samples were collected every 5 min for determination of plasma glucose and 
insulin. Insulin sensitivity was assessed as the mean glucose infusion rate during the last 40 min. In the 
stationary equilibrium, the amount of glucose administered (M) equals the glucose taken by the body 
tissues and is a measure of overall insulin sensitivity.  
 
Statistical analysis. 
Values are expressed as means ± s.e.m. The differences between groups were assessed using non-
parametric Mann-Whitney test or an unpaired Student's t-test (two-sided). Values were considered 
significant at P < 0.05. For human data, given the sample size, non-parametric Mann-Whitney test was 
used to assess the differences between 2 groups or Kruskal-Wallis for multiple comparisons. 
Spearman's rank correlation coefficient (r) was used to analyze the correlations between Kyn and 
metabolic and clinical parameters in subjects with obesity. Differences corresponding to P < 0.05 were 
considered significant. Statistical analysis was performed with GraphPad Prism (San Diego, CA, 
USA). 
Life Sciences Reporting Summary. 
Further information on experimental design is available in the Life Sciences Reporting Summary. 
Data availability 
The data for the findings of this study are available from the corresponding author upon reasonable 
request. European Nucleotide Archive: the sequencing data are deposited under accession number 
PRJEB25438.  
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